AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9563813 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi modal day program
Number of subjects: 73
Study 9563813 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 73
Study 7943586 — intervention group
Group type: EXPERIMENTAL
Intervention: Resection with primary anastomosis
Number of subjects: 60
Study 7943586 — intervention group
Group type: COMPARATOR
Intervention: Ileocolostomies
Number of subjects: 60
Study 3207549 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral ilioinguinal nerve blockade using 0.5% plain bupivacaine 10 ml to each side
Number of subjects: 13
Study 3207549 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nerve blockade)
Number of subjects: 13
Study 29427701 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day; n=20)
Number of subjects: 40
Study 29427701 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (10 mg/day; n=20)
Number of subjects: 40
Study 29427701 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 40
Study 29427701 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 40
Study 27435286 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification Treatment (ABMT)
Number of subjects: 67
Study 27435286 — intervention group
Group type: COMPARATOR
Intervention: Attention Control Training (ACT)
Number of subjects: 67
Study 25703737 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised video-enhanced feedback (UVF)
Number of subjects: 32
Study 25703737 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized video feedback (IVF)
Number of subjects: 32
Study 25703737 — intervention group
Group type: COMPARATOR
Intervention: Standard lecture feedback
Number of subjects: 32
Study 23154449 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP withdrawal (subtherapeutic CPAP)
Number of subjects: 41
Study 23154449 — intervention group
Group type: COMPARATOR
Intervention: Continuing therapeutic CPAP
Number of subjects: 41
Study 20210906 — intervention group
Group type: EXPERIMENTAL
Intervention: Football group (FG)
Number of subjects: 50
Study 20210906 — intervention group
Group type: EXPERIMENTAL
Intervention: Running group (RG)
Number of subjects: 50
Study 20210906 — intervention group
Group type: COMPARATOR
Intervention: Control group (CO)
Number of subjects: 50
Study 18156881 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower tidal volumes of 6 ml/kg and 10 cm H2O PEEP
Number of subjects: 40
Study 18156881 — intervention group
Group type: COMPARATOR
Intervention: Higher tidal volumes of 12 ml/kg ideal body weight and no positive end-expiratory pressure (PEEP)
Number of subjects: 40
Study 18156881 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (lower tidal volumes and higher tidal volumes)
Number of subjects: 40
Study 15696037 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound scanning (CUS) with a bolus of 1.5 to 2.4 mL of a second generation blood pool contrast agent
Number of subjects: 18
Study 11796347 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruprintrivir (4 mg single dose)
Number of subjects: 0
Study 11796347 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruprintrivir (8 mg single dose)
Number of subjects: 0
Study 11796347 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruprintrivir (multiple doses every 3 h, six times per day for 7 days)
Number of subjects: 0
Study 11796347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10363622 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal tramadol (1 mg/kg)
Number of subjects: 40
Study 10363622 — intervention group
Group type: COMPARATOR
Intervention: 0.25% plain bupivacaine (0.5 ml/kg)
Number of subjects: 40
Study 8590268 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 0.1% ophthalmic solution
Number of subjects: 20
Study 8590268 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2209147 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized pentamidine (AP)
Number of subjects: 36
Study 2209147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 6449801 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine solution
Number of subjects: 64
Study 6449801 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine gel
Number of subjects: 64
Study 6449801 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 64
Study 31927518 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral and written education using aspirin booklet
Number of subjects: 12
Study 31098615 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet (KD) - 15% carbohydrate, 60% fat, 25% protein
Number of subjects: 11
Study 31098615 — intervention group
Group type: COMPARATOR
Intervention: High-Carbohydrate, Low-Fat Diet (HCLF) - 55% carbohydrate, 20% fat, 25% protein
Number of subjects: 11
Study 28426359 — intervention group
Group type: EXPERIMENTAL
Intervention: Drop-in center linkage (n = 40)
Number of subjects: 79
Study 28426359 — intervention group
Group type: COMPARATOR
Intervention: Shelter linkage (n = 39)
Number of subjects: 79
Study 26727825 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of bevacizumab 1.25 mg/0.05 mL (Avastin)
Number of subjects: 20
Study 26727825 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of triamcinolone acetonid 4 mg/0.1 mL (Kenalog)
Number of subjects: 20
Study 23460711 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil (FU) ‐based chemotherapy with irinotecan (IRI)
Number of subjects: 123
Study 19375557 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS)
Number of subjects: 1698
Study 19375557 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) with antiglycemic medications
Number of subjects: 1698
Study 17298589 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide + insulin glargine
Number of subjects: 55
Study 17298589 — intervention group
Group type: COMPARATOR
Intervention: Placebo + insulin glargine
Number of subjects: 55
Study 15294641 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbiotic containing Bifidobacterium animalis and inulin
Number of subjects: 49
Study 15294641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 11377114 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment sooner
Number of subjects: 0
Study 11377114 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study 10719591 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutting instruments
Number of subjects: 100
Study 10719591 — intervention group
Group type: COMPARATOR
Intervention: Non-cutting instruments
Number of subjects: 100
Study 8957747 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (3 month course)
Number of subjects: 18
Study 8957747 — intervention group
Group type: COMPARATOR
Intervention: Control (retrobulbar irradiation)
Number of subjects: 18
Study 1313761 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat high-fibre diet
Number of subjects: 30
Study 1313761 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched)
Number of subjects: 30
Study 3893389 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin infusion when COP fell below 24 cm H2O
Number of subjects: 220
Study 3893389 — intervention group
Group type: COMPARATOR
Intervention: Albumin infusion when COP fell below 29 cm H2O
Number of subjects: 220
Study 31707865 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling + functional electrical stimulation with interval pattern
Number of subjects: 30
Study 31707865 — intervention group
Group type: COMPARATOR
Intervention: Cycling + functional electrical stimulation with linear pattern
Number of subjects: 30
Study 29785414 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymetazoline (0.05%)
Number of subjects: 128
Study 29785414 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 128
Study 27130954 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent pairing of sounds with distinct visual objects
Number of subjects: 49
Study 27130954 — intervention group
Group type: COMPARATOR
Intervention: Random pairing of sounds with distinct visual objects
Number of subjects: 49
Study 25352870 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment guidelines (STG) intervention group
Number of subjects: 0
Study 25352870 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 0
Study 23600305 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton-photon therapy with proton beam 220Mev, focal dose of 28-28.8 Gy-eq for 8, 5 or 3 fractions (3, 4 or 5.5 Gy-eq)
Number of subjects: 272
Study 23600305 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton-photon therapy
Number of subjects: 272
Study 23600305 — intervention group
Group type: COMPARATOR
Intervention: Control group with local 4-dipole photon irradiation to 68-72 Gy in 12-14 fractions of 2 Gy
Number of subjects: 272
Study 23600305 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 272
Study 20332612 — intervention group
Group type: EXPERIMENTAL
Intervention: Serenoa repens + selenium and lycopene (Profluss)
Number of subjects: 102
Study 20332612 — intervention group
Group type: COMPARATOR
Intervention: S. repens alone
Number of subjects: 102
Study 18627368 — intervention group
Group type: EXPERIMENTAL
Intervention: Interrupted sevoflurane administration (SevoI)
Number of subjects: 42
Study 18627368 — intervention group
Group type: COMPARATOR
Intervention: Propofol-only (P)
Number of subjects: 42
Study 18627368 — intervention group
Group type: COMPARATOR
Intervention: Continuous sevoflurane administration (SevoC)
Number of subjects: 42
Study 16173137 — intervention group
Group type: EXPERIMENTAL
Intervention: PYY infusion
Number of subjects: 8
Study 16173137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 16173137 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejunal feeding
Number of subjects: 8
Study 12079004 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg nizatidine
Number of subjects: 5
Study 12079004 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg nizatidine
Number of subjects: 5
Study 12079004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 10451167 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide (initial dose of 4 mg, followed by 2 mg after each unformed stool, up to 8 mg/d) plus Oral Rehydration Therapy (ORT) (500 mL initially, followed by 250 mL after each subsequently passed unformed stool, up to 1,000 mL per 24 hours)
Number of subjects: 80
Study 10451167 — intervention group
Group type: COMPARATOR
Intervention: Loperamide (initial dose of 4 mg, followed by 2 mg after each unformed stool, up to 8 mg/d)
Number of subjects: 80
Study 7575286 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fluconazole
Number of subjects: 196
Study 7575286 — intervention group
Group type: COMPARATOR
Intervention: Topical antifungals (nystatin and amphotericin B suspensions)
Number of subjects: 196
Study 2154513 — intervention group
Group type: EXPERIMENTAL
Intervention: Low‐fat, low‐cholesterol diet (LFLC)
Number of subjects: 71
Study 2154513 — intervention group
Group type: EXPERIMENTAL
Intervention: Low‐fat, low‐cholesterol diet plus 50 gm/day oat bran (LFLC + OB)
Number of subjects: 71
Study 2154513 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 gm/day oat bran supplemented diet (OB)
Number of subjects: 71
Study 2154513 — intervention group
Group type: EXPERIMENTAL
Intervention: 42.5 gm/day processed oat bran (POB)
Number of subjects: 71
Study 30295811 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab induction
Number of subjects: 895
Study 30295811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 895
Study 30302465 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubiquinol (200 mg d‐1)
Number of subjects: 10
Study 30302465 — intervention group
Group type: COMPARATOR
Intervention: Ubiquinone (200 mg d‐1)
Number of subjects: 10
Study 26410819 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body static stretching (SS)
Number of subjects: 0
Study 26410819 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body dynamic stretching (DS)
Number of subjects: 0
Study 26410819 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper body static stretching (SS)
Number of subjects: 0
Study 26410819 — intervention group
Group type: COMPARATOR
Intervention: Dynamic ROM and muscle force and activation variables
Number of subjects: 0
Study 25193889 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic distal clavicle resection (DCR)
Number of subjects: 78
Study 25193889 — intervention group
Group type: COMPARATOR
Intervention: No additional intervention (Control group)
Number of subjects: 78
Study 22795238 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocain 1% adjunction
Number of subjects: 154
Study 22795238 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacain 0.25% adjunction
Number of subjects: 154
Study 22795238 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular contrast injection only
Number of subjects: 154
Study 20519902 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymyxin B hemoperfusion
Number of subjects: 64
Study 20519902 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 64
Study 18660500 — intervention group
Group type: EXPERIMENTAL
Intervention: AirWay Scope (AWS)
Number of subjects: 13
Study 18660500 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 13
Study 15591082 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscoelastic gel
Number of subjects: 49
Study 15591082 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (Control)
Number of subjects: 49
Study 12860861 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe CHF patients
Number of subjects: 45
Study 12860861 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 45
Study 11120532 — intervention group
Group type: EXPERIMENTAL
Intervention: Myometrial sampling at cesarean delivery
Number of subjects: 354
Study 11120532 — intervention group
Group type: COMPARATOR
Intervention: Control group (no myometrial sampling)
Number of subjects: 354
Study 8890060 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR) with expanded Polytetrafluoroethylene barrier membranes
Number of subjects: 10
Study 8890060 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (debridement only)
Number of subjects: 10
Study 1503621 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin-A (CsA)
Number of subjects: 116
Study 1503621 — intervention group
Group type: COMPARATOR
Intervention: Antithymocyte globulin (ATG) with prednisone (PDN)
Number of subjects: 116
Study 1503621 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential immunosuppressive therapy (alternative therapy after no or minimal response)
Number of subjects: 116
Study 1503621 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 116
Study 1503621 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute neutrophil count (ANC) at entry
Number of subjects: 116
Study 6366617 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (50 mg every three weeks for two years)
Number of subjects: 16
Study 6366617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30999957 — intervention group
Group type: EXPERIMENTAL
Intervention: LLIN + IRS
Number of subjects: 34458
Study 30999957 — intervention group
Group type: EXPERIMENTAL
Intervention: LLIN
Number of subjects: 34458
Study 30999957 — intervention group
Group type: EXPERIMENTAL
Intervention: IRS
Number of subjects: 34458
Study 30999957 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 34458
Study 30999957 — intervention group
Group type: EXPERIMENTAL
Intervention: All arms
Number of subjects: 34458
Study 30144169 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated tucking (FT)
Number of subjects: 50
Study 26894180 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA)
Number of subjects: 29
Study 26894180 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Level Laser Therapy (LLLT)
Number of subjects: 29
Study 25068219 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamate injection
Number of subjects: 15
Study 25068219 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline injection
Number of subjects: 15
Study 21685792 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diltiazem cream
Number of subjects: 134
Study 21685792 — intervention group
Group type: COMPARATOR
Intervention: Botulinum toxin A (BTA)
Number of subjects: 134
Study 19708174 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin therapy throughout pregnancy
Number of subjects: 59
Study 19708174 — intervention group
Group type: COMPARATOR
Intervention: No metformin therapy throughout pregnancy (Control)
Number of subjects: 59
Study 17977295 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily topical applications of a dental cream containing CPP‐ACP (Topacal) for 3 months followed by a 3‐month period of daily toothbrushing with fluoridated dentifrice.
Number of subjects: 26
Study 17977295 — intervention group
Group type: COMPARATOR
Intervention: Daily 0.05% sodium fluoride mouthwash combined with fluoridated dentifrice for 6 months.
Number of subjects: 26
Study 17977295 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (CPP‐ACP and fluoride mouthwash)
Number of subjects: 26
Study 15903281 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 43
Study 15903281 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen
Number of subjects: 43
Study 15903281 — intervention group
Group type: COMPARATOR
Intervention: Control (no supplementary medication)
Number of subjects: 43
Study 12553505 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg meloxicam
Number of subjects: 272
Study 12553505 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg meloxicam
Number of subjects: 272
Study 12553505 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (2 x 50 mg a day)
Number of subjects: 272
Study 9623748 — intervention group
Group type: EXPERIMENTAL
Intervention: Sophisticated simulator group (feigned impairment with TBI information)
Number of subjects: 60
Study 9623748 — intervention group
Group type: EXPERIMENTAL
Intervention: Naive simulator group (feigned impairment without TBI information)
Number of subjects: 60
Study 9623748 — intervention group
Group type: COMPARATOR
Intervention: Control group (instructed to perform optimally)
Number of subjects: 60
Study 9623748 — intervention group
Group type: EXPERIMENTAL
Intervention: TBI subjects (completed neuropsychological evaluations)
Number of subjects: 60
Study 9623748 — intervention group
Group type: EXPERIMENTAL
Intervention: Discriminate function analysis cutting score
Number of subjects: 60
Study 9623748 — intervention group
Group type: EXPERIMENTAL
Intervention: Previously investigated cutting scores
Number of subjects: 60
Study 8593196 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilized stannous fluoride dentifrice
Number of subjects: 0
Study 8593196 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 0
Study 2540392 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint Intervals (SI)
Number of subjects: 25
Study 2540392 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance (E)
Number of subjects: 25
Study 2540392 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination (C)
Number of subjects: 25
Study 1198015 — intervention group
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block with 10 ml of 0.5% Marcaine
Number of subjects: 0
Study 1198015 — intervention group
Group type: COMPARATOR
Intervention: Intra articular hydrocortisone injection (50 mg of hydrocortisone acetate into the glenohumeral joint)
Number of subjects: 0
Study 31708295 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI with systematic and targeted biopsy
Number of subjects: 273
Study 31708295 — intervention group
Group type: COMPARATOR
Intervention: 12-core systematic sampling (non-MRI)
Number of subjects: 273
Study 30095747 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma interleukin-1 receptor antagonist (IL-1ra) levels on day 0
Number of subjects: 549
Study 30095747 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma interleukin-1 receptor antagonist (IL-1ra) levels across all days
Number of subjects: 549
Study 30095747 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma interleukin-1 receptor antagonist (IL-1ra) levels on day 2
Number of subjects: 549
Study 30095747 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma interleukin-1 receptor antagonist (IL-1ra) levels on day 1
Number of subjects: 549
Study 30095747 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma interleukin-1 receptor antagonist (IL-1ra) levels
Number of subjects: 549
Study 28962661 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnamomum zeylanicum extract (250 mg)
Number of subjects: 210
Study 28962661 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnamomum zeylanicum extract (500 mg)
Number of subjects: 210
Study 28962661 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose monohydrate)
Number of subjects: 210
Study 26383034 — intervention group
Group type: EXPERIMENTAL
Intervention: Body acupuncture (Shuigou GV 26, Neiguan PC 6, and Zusanli ST 36)
Number of subjects: 68
Study 26383034 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine and minimal nontraditional acupuncture (minimally active penetrating)
Number of subjects: 68
Study 22510162 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Strength Training for Upper Limbs (FST-UL)
Number of subjects: 58
Study 22510162 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Strength Training for Lower Limbs (FST-LL)
Number of subjects: 58
Study 22510162 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Strength Training (FST)
Number of subjects: 58
Study 21533539 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 81
Study 21533539 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical treatment
Number of subjects: 81
Study 18081747 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine combined with dipyridamole
Number of subjects: 64
Study 18081747 — intervention group
Group type: COMPARATOR
Intervention: Desloratadine only (Control)
Number of subjects: 64